acetylcarnitine has been researched along with Multiple Myeloma in 2 studies
Acetylcarnitine: An acetic acid ester of CARNITINE that facilitates movement of ACETYL COA into the matrices of mammalian MITOCHONDRIA during the oxidation of FATTY ACIDS.
Multiple Myeloma: A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Retreatment with bortezomib (B) is often considered for patients with relapsed multiple myeloma (MM), but this strategy is hindered by uncertainty of response and emergence of B-induced peripheral neuropathy (PN)." | 9.19 | Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Netwo ( Asimakopoulos, F; Callander, N; Campbell, T; Eickhoff, J; Go, R; Hegeman, R; Hematti, P; Hutson, P; Longo, W; Markovina, S; Miyamoto, S; Williams, E, 2014) |
| "Retreatment with bortezomib (B) is often considered for patients with relapsed multiple myeloma (MM), but this strategy is hindered by uncertainty of response and emergence of B-induced peripheral neuropathy (PN)." | 6.79 | Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Netwo ( Asimakopoulos, F; Callander, N; Campbell, T; Eickhoff, J; Go, R; Hegeman, R; Hematti, P; Hutson, P; Longo, W; Markovina, S; Miyamoto, S; Williams, E, 2014) |
| "Retreatment with bortezomib (B) is often considered for patients with relapsed multiple myeloma (MM), but this strategy is hindered by uncertainty of response and emergence of B-induced peripheral neuropathy (PN)." | 5.19 | Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Netwo ( Asimakopoulos, F; Callander, N; Campbell, T; Eickhoff, J; Go, R; Hegeman, R; Hematti, P; Hutson, P; Longo, W; Markovina, S; Miyamoto, S; Williams, E, 2014) |
| "Retreatment with bortezomib (B) is often considered for patients with relapsed multiple myeloma (MM), but this strategy is hindered by uncertainty of response and emergence of B-induced peripheral neuropathy (PN)." | 2.79 | Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Netwo ( Asimakopoulos, F; Callander, N; Campbell, T; Eickhoff, J; Go, R; Hegeman, R; Hematti, P; Hutson, P; Longo, W; Markovina, S; Miyamoto, S; Williams, E, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lodi, A | 1 |
| Tiziani, S | 1 |
| Khanim, FL | 1 |
| Günther, UL | 1 |
| Viant, MR | 1 |
| Morgan, GJ | 1 |
| Bunce, CM | 1 |
| Drayson, MT | 1 |
| Callander, N | 1 |
| Markovina, S | 1 |
| Eickhoff, J | 1 |
| Hutson, P | 1 |
| Campbell, T | 1 |
| Hematti, P | 1 |
| Go, R | 1 |
| Hegeman, R | 1 |
| Longo, W | 1 |
| Williams, E | 1 |
| Asimakopoulos, F | 1 |
| Miyamoto, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective Long-term Observational Study in Patients With Monoclonal Gammopathy of Undetermined Significance[NCT05539079] | 2,000 participants (Anticipated) | Observational | 2023-09-06 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for acetylcarnitine and Multiple Myeloma
| Article | Year |
|---|---|
Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Netwo
Topics: Acetylcarnitine; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Drug | 2014 |
1 other study available for acetylcarnitine and Multiple Myeloma
| Article | Year |
|---|---|
Proton NMR-based metabolite analyses of archived serial paired serum and urine samples from myeloma patients at different stages of disease activity identifies acetylcarnitine as a novel marker of active disease.
Topics: Acetylcarnitine; Aged; Aged, 80 and over; Biomarkers, Tumor; Carnitine; Clinical Trials, Phase III a | 2013 |